Pfizer Inc. $PFE Position Boosted by GRIMES & Co WEALTH MANAGEMENT LLC

GRIMES & Co WEALTH MANAGEMENT LLC grew its position in Pfizer Inc. (NYSE:PFE) by 647.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 789,950 shares of the biopharmaceutical company’s stock after acquiring an additional 684,303 shares during the quarter. GRIMES & Co WEALTH MANAGEMENT LLC’s holdings in Pfizer were worth $19,670,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of PFE. Horizon Financial Services LLC increased its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. YANKCOM Partnership acquired a new position in Pfizer in the 4th quarter worth about $28,000. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer in the 3rd quarter worth about $29,000. Darwin Wealth Management LLC acquired a new position in Pfizer in the 2nd quarter worth about $32,000. Finally, Torren Management LLC acquired a new position in Pfizer in the 4th quarter worth about $34,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PFE shares. Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Monday, March 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.74.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 beat and guidance reaffirmed: Pfizer reported better-than-expected Q1 revenue and EPS and reiterated FY2026 guidance, reinforcing the company’s transition beyond pandemic-driven sales and supporting near-term earnings visibility. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Oncology momentum: Recent FDA approval (VEPPANU) and positive Phase 3 data (ELREXFIO) bolster Pfizer’s oncology franchise, which is a key driver of longer-term growth and valuation upside. Pfizer Oncology Advances Raise New Questions For Valuation And Momentum
• Positive Sentiment: Dividend credibility restored: Coverage highlighting management’s actions has reduced concerns about Pfizer being a yield trap, supporting investor confidence in the roughly 6.5% yield. Pfizer’s 6.5% Dividend Yield Looked Too Good to Be True — but Management Just Silenced the Skeptics
• Positive Sentiment: Unusual call buying: Large intraday options activity — ~254,818 calls (≈84% above normal daily call volume) — signals some traders are taking bullish, leveraged positions that could amplify upside moves if news flows remain positive.
• Neutral Sentiment: Lyme vaccine dosing trial update: A new fifth‑dose VLA15 trial was announced; it signals ongoing R&D optimization but outcome/timing uncertainty limits immediate stock impact. Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors
• Neutral Sentiment: Mixed analyst views and valuation debate: Analysts differ on PFE’s forward momentum and valuation after Q1 — that keeps sentiment mixed and may limit large directional moves until clearer catalysts arrive. Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Compass Therapeutics (CMPX)
• Negative Sentiment: Trial termination trims oncology upside: Pfizer ended a Phase 1b/2 lymphoma combo trial, removing a small piece of future oncology optionality and introducing modest near-term disappointment for pipeline bulls. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Pfizer Stock Performance

Shares of NYSE PFE opened at $26.48 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.87 and a current ratio of 1.25. The firm has a market cap of $150.90 billion, a price-to-earnings ratio of 20.21 and a beta of 0.35. The business’s 50-day simple moving average is $27.14 and its 200-day simple moving average is $26.16. Pfizer Inc. has a 52 week low of $21.97 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.